Pell v. Kill

135 A.3d 764
CourtCourt of Chancery of Delaware
DecidedMay 19, 2016
DocketC.A. 12251-VCL
StatusPublished
Cited by28 cases

This text of 135 A.3d 764 (Pell v. Kill) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pell v. Kill, 135 A.3d 764 (Del. Ct. App. 2016).

Opinion

OPINION

LASTER, Vice Chancellor.

Nominal defendant Cogentix Medical, Inc. (the “Gompany”) has scheduled its annual meeting for May 20, 2016 (the “Annual Meeting”). Before the actions challenged in this case, its board of directors (the “Board”) had eight seats staggered into three classes. Three were designated for Class I directors, three for Class II directors, and two for Class III directors. The Class I directors will stand for election at the Annual Meeting.

Before the events giving rise to this litigation, the eight members of the Board were aligned' to varying degrees with either plaintiff Lewis C. Pell or defendant Robert C. Kill. Pell is a Class I director and the Company’s largest stockholder. He was a co-founder and Chairman of the Board of Vision-Sciences, Inc. (“VSI”), one *769 of two constituent corporations that merged to form Cogentix.. Two other members of the Board .were former directors of VSI.

Kill is a Class III director and the Company’s incumbent CEO, President,, and Chairman of the Board. He was CEO, President, and . Chairman of Uroplasty, Inc., the. .second of the. two constituent corporations that merged to, form Cogen-tix. Four other members of the Board were former directors of Uroplasty.

On February .16, 2016, Pell filed an amendment to his Schedule 13D in which he publicly disclosed his intention to seek changes in the composition of the Board and the management team. The other directors understood that if Pell did not get his way, he intended to wage a proxy contest to elect himself and two allies as Class I directors. Over the next six weeks, it became clear that Pell wanted Kill terminated and Kill’s closest allies, defendants Kenneth H. Paulus and Kevin H. Roche, to leave the Board.

The directors other than Pell and Kill attempted to find a negotiated solution, but Kill, Paulus, and Roche needed a Plan B. One of the Class I seats was held by a legacy-Uroplasty director, so if the negotiations failed, Pell’s .proxy contest could change the balance in the boardroom from a five-to-three majority to a four-to-four deadlock. Matters became more serious when a legacy-Uroplasty director in Class II resigned. At that point, if Pell succeeded in electing three Class I directors, the balancé could flip to a four-to-three majority in Pell’s favor. '

As their Plan B, Kill, Paulus, and Roche developed a strategy to shrink the size of the Board from eight seats to five and reduce the number of Class I seats to one (the “Board Reduction Plan”). During a meeting of the Board held on March 29, 2016, the directors voted along party lines to approve the Board Reduction, Plan. A reduction from eight seats to seven took place immediately, eliminating the vacancy created by the resignation of the Class II director. The reduction from seven seats to five will become effective at the Annual Meeting. Kill, Roche, and Paulus voted in favor. So did the fourth legacy-Uroplasty director, defendant James P. Stauner, who had decided not to stand for re-election. Pell and the two legacy-VSI directors voted against.

• Through the Board Reduction Plan, Kill, Roche, Paulus, and Stauner (the “Defendant Directors”) sought to preserve the legacy-Uroplasty directors’ control over the Board and neutralize the threat of Pell’s proxy contest. Before the Board Reduction Plan, the Company’s stockholders had the opportunity to elect three nominees to the Class I seats, potentially establishing a new Board majority. By reducing the number of Class I seats, the Defendant Directors ensured that no matter how the stockholders voted, they would retain a three-to-two majority.

Although the point is contested, 1 assume for purposes of analysis that the Defendant Directors sought to preserve their control not to extract personal benefits, but rather for the selfless purpose of overseeing, a thorough and deliberative process after the Annual Meeting to reconstitute the Board with independent directors that they would identify, vet, and select. The problem is that when facing an . electoral contest, incumbent directors are not entitled to determine the outcome for the. stockholders. Stockholders elect directors, not the other way around. Even assuming that the Defendant Directors acted for an unselfish purpose, they still acted inequitably. A preliminary injunction shall issue enjoining the Company from implementing the portion of the Board Reduction Plan- that- otherwise *770 would become effective at the Annual Meeting.

I. FACTUAL BACKGROUND

The facts are drawn from the record, developed in connection with the application for a preliminary injunction. The parties have submitted numerous documentary exhibits and deposition testimony from five fact witnesses.

After the depositions were completed, both sides submitted affidavits from witnesses who had been deposed. The affi-ants’ counsel could have elicited the aver-ments in the affidavits when the witnesses’ depositions were taking place, as they did on other matters. Had they done so, opr posing counsel could have tested the assertions through cross-examination. Because the lawyers eschewed that course, this decision largely discounts the affidavits. 1 It relies most heavily on the contemporaneous documents.

What follows are the facts as they are likely to be found after trial, based on the current record. This is a probabilistic exercise. To make the implicit explicit, the eventual, findings of fact after trial could be. different.

A. The Company And Its Governance Structure

Cogentix is a Delaware corporation headquartered in Minnetonka, Minnesota. The Company designs, develops, manufactures,' and markets medical device products for specialty medical markets, such as urology, gynecology, and bariatric medicine. Its common stock trades on NASDAQ under the symbol “CGNT.”

Cogentix was formed through a stock-for-stock merger between two NASDAQ-listed ' companies: VSI and Uroplasty, The transaction closed on March 31, 2015 (the “Merger”). Technically, VSI acquired Uroplasty through a reverse-triangular merger. After the transaction closed, VSI changed its name to Cogentix.

In corporate governance terms, Uro-plasty was the acquirer. Its former stockholders emerged owning approximately 62.5% of Cogentix, and its management team continued at the helm of the combined company. Kill had been Uroplasty’s President, CEO, and Chairman of the Board before the Merger. ■ He assumed the same roles at Cogentix. Non-party Brett Reynolds had been Uroplasty’s Chief Financial Officer. He took on that role for Cogentix.

More importantly for present purposes, legacy-Uroplasty directors commanded a majority of the Company’s eight board seats. Five seats were held by former directors of Uroplasty, comprising the Defendant Directors and non-party Sven A. Wehrwein. Three seats were held by former directors of VSI, comprising Pell and non-parties Cheryl Pegus and Howard I. Zauberman.

For Pell and Zauberman, the Merger involved stepping back from more active roles at VSI. Pell was VSI’s co-founder and its Chairman.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Roy Mitchell Edmondson v. Daniel Oakes
Court of Chancery of Delaware, 2026
NEC Fund VI HE Lender, LLC v. Hecate Holdings LLC
Court of Chancery of Delaware, 2026
Fortiline, Inc. v. Hayne McCall
Court of Chancery of Delaware, 2024
Palkon v. Maffei
Court of Chancery of Delaware, 2024
Paragon Technologies, Inc. v. Terence J. Cryan
Court of Chancery of Delaware, 2023
CCSB Financial Corp. v. Deann M. Totta
Supreme Court of Delaware, 2023
In re Columbia Pipeline Group, Merger Litigation
Court of Chancery of Delaware, 2023
Coster v. UIP Companies, Inc.
Supreme Court of Delaware, 2023
Sternlicht v. Hernandez
Court of Chancery of Delaware, 2023
New Enterprise Associates 14, L.P. v. Rich
Court of Chancery of Delaware, 2023
In Re Edgio, Inc. Stockholders Litigation
Court of Chancery of Delaware, 2023
Kodiak Building Partners, LLC v. Philip D. Adams
Court of Chancery of Delaware, 2022
Deann M. Totta v. CCSB Financial Corp.
Court of Chancery of Delaware, 2022

Cite This Page — Counsel Stack

Bluebook (online)
135 A.3d 764, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pell-v-kill-delch-2016.